This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
by Zacks Equity Research
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
by Zacks Equity Research
AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.
Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.
Why Earnings Season Could Be Great for TESARO (TSRO)
by Zacks Equity Research
TESARO (TSRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Intrexon (XON) in this Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
Is Zoetis (ZTS) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.
What's in the Cards for Endo (ENDP) this Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) remains focused on providing updates on its restructuring efforts across the Generics product as well as its manufacturing facility network in Q2.
What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.
Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2.
What's in Store for Agios Pharma (AGIO) in Q2 Earnings?
by Zacks Equity Research
Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.
What's in Store for Conatus (CNAT) this Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
by Zacks Equity Research
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.
Is the Options Market Predicting a Spike in TESARO, Inc. (TSRO) Stock?
by Zacks Equity Research
Options Market is Predicting a Spike in TESARO, Inc. (TSRO) Stock on the back of its surging implied volatility.
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.
Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Clovis Oncology (CLVS) opened more than 40% higher on Monday morning after the company announced positive results in a late-stage trial involving its Rubraca therapy--an outcome that could help widen the use of the drug and give Clovis a competitive edge.
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
by Zacks Equity Research
Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
by Zacks Equity Research
On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).
What Makes Tesaro (TSRO) a Strong Sell?
by Zacks Equity Research
Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
by Zacks Equity Research
TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.
Do Options Traders Know Something About Tesaro (TSRO) Stock We Don't?
by Zacks Equity Research
Options traders are pricing in a big move for Tesaro (TSRO) shares as it has huge implied volatility.